Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Short Reports

Preservatives in Insulin Preparations Impair Leukocyte Function: In vitro study

  1. Ineke van Faassen, MD,
  2. A Marian JJ Verweij-van Vught, MD,
  3. Mary Z Lomecky-Janousek, BSc,
  4. Peter PA Razenberg, MD and
  5. Eduard A van der Veen, MD
  1. Departments of Endocrinology and Medical Microbiology, Free University Hospital Amsterdam, The Netherlands
  1. Address correspondence and reprint requests to Ineke van Faassen, MD, Department of Endocrinology, Free University Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlands.
Diabetes Care 1990 Jan; 13(1): 71-74. https://doi.org/10.2337/diacare.13.1.71
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

m-Cresol and methyl p-hydroxybenzoate are preservatives in insulin preparations. As previously reported, in diabetic patients on continuous subcutaneous insulin infusion, users of insulin-containing m-cresol had significantly more inflamed infusion sites than users of insulin with methyl p-hydroxybenzoate. This study assessed the influence of insulin with and without these preservatives on leukocyte function. Leukocyte function was investigated in a killing experiment, expressed as the percentage of bacteria killed after 60 min incubation of bacteria (Staphylococcus aureus), polymorphonuclear leukocytes, serum, and insulin preparations. Because preservative is retained by the infusion device, insulin with preservative was tested before and after 1 and 4 days perfusion with a PVC pump catheter. After perfusion, the amount of preservative was reduced (percentage of original concentration after 1 and 4 days 8 and 30% m-cresol and 42 and 72% methyl p-hydroxybenzoate, respectively). The killing percentage in insulin with m-cresol reduced compared with insulin without preservative (mean ± SE 95.4 ± 0.8%) and the control without insulin (95.8 ± 0.8%), both before and after 1 and 4 days perfusion (74.8 ± 0.7, 80.2 ± 2.8, and 80.6 ± 1.6%, respectively; P < 0.01). The same occurred in insulin with methyl p-hydroxybenzoate (85.0 ± 0.9% before and 88.4 ± 0.9 and 86.2 ± 0.8% after 1 and 4 days perfusion; P < 0.05). All insulin preparations with m-cresol caused lower killing percentages than corresponding insulin preparations with methyl p-hydroxybenzoate (P < 0.05). These results demonstrate that both preservatives impaired leukocyte function, but m-cresol was the most noxious in this respect. This indicates that preservatives in insulin preparations are possibly implicated in the pathogenesis of local infections in continuous subcutaneous insulin infusion.

  • Received December 5, 1988.
  • Revision received July 19, 1989.
  • Accepted July 19, 1989.
  • Copyright © 1990 by the American Diabetes Association

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this Issue

January 1990, 13(1)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preservatives in Insulin Preparations Impair Leukocyte Function: In vitro study
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Preservatives in Insulin Preparations Impair Leukocyte Function: In vitro study
Ineke van Faassen, A Marian JJ Verweij-van Vught, Mary Z Lomecky-Janousek, Peter PA Razenberg, Eduard A van der Veen
Diabetes Care Jan 1990, 13 (1) 71-74; DOI: 10.2337/diacare.13.1.71

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Preservatives in Insulin Preparations Impair Leukocyte Function: In vitro study
Ineke van Faassen, A Marian JJ Verweij-van Vught, Mary Z Lomecky-Janousek, Peter PA Razenberg, Eduard A van der Veen
Diabetes Care Jan 1990, 13 (1) 71-74; DOI: 10.2337/diacare.13.1.71
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Injection Site Effects on the Pharmacokinetics and Glucodynamics of Insulin Lispro and Regular Insulin
  • Mitochondrial Aldehyde Dehydrogenase in Diabetes Associated With Mitochondrial tRNALeu(UUR) Mutation at Position 3243
  • NIDDM, Impaired Glucose Tolerance, and Pulmonary Function in Older Adults: The Rancho Bernardo Study
Show more Short Reports

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.